208 related articles for article (PubMed ID: 26459210)
1. Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB.
Li D; Gao N; Zhu N; Lin Y; Li Y; Chen M; You X; Lu Y; Wan K; Jiang JD; Jiang W; Si S
Bioorg Med Chem Lett; 2015 Nov; 25(22):5178-81. PubMed ID: 26459210
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of substituted 2-acylamide-1,3-benzo[d]zole analogues as agents against MDR- and XDR-MTB.
Li D; Liu C; Jiang X; Lin Y; Zhang J; Li Y; You X; Jiang W; Chen M; Xu Y; Si S
Eur J Med Chem; 2021 Jan; 209():112898. PubMed ID: 33069433
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: in vitro, structure-activity relationship, pharmacokinetics and in vivo evaluation.
Munagala G; Yempalla KR; Singh S; Sharma S; Kalia NP; Rajput VS; Kumar S; Sawant SD; Khan IA; Vishwakarma RA; Singh PP
Org Biomol Chem; 2015 Mar; 13(12):3610-24. PubMed ID: 25670502
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
[TBL] [Abstract][Full Text] [Related]
7. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
[TBL] [Abstract][Full Text] [Related]
8. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
9. [The effects of gene mutation related to drug resistance and drug efflux pump in extensively drug-resistant tuberculosis clinical isolates].
Cui ZL; Wang XL; Wang J; Lu JM; Hu ZY
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jul; 33(7):505-9. PubMed ID: 20979796
[TBL] [Abstract][Full Text] [Related]
10. Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.
Bakal RL; Gattani SG
Eur J Med Chem; 2012 Jan; 47(1):278-82. PubMed ID: 22088956
[TBL] [Abstract][Full Text] [Related]
11.
Deb PK; Al-Shar'i NA; Venugopala KN; Pillay M; Borah P
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):869-884. PubMed ID: 34060396
[TBL] [Abstract][Full Text] [Related]
12. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
[TBL] [Abstract][Full Text] [Related]
13. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
Chae H; Shin SJ
J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
[TBL] [Abstract][Full Text] [Related]
14. [Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Zhang LL; Yang H; Xiao HP; Lu JM; Sha W; Zhang Q
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jun; 39(6):464-8. PubMed ID: 27289577
[TBL] [Abstract][Full Text] [Related]
15. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.
Lilienkampf A; Pieroni M; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2010 Jan; 53(2):678-88. PubMed ID: 20000577
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and characterization of drug-resistant tuberculosis in a local hospital of Northeast China.
Yang Y; Zhou C; Shi L; Meng H; Yan H
Int J Infect Dis; 2014 May; 22():83-6. PubMed ID: 24556164
[TBL] [Abstract][Full Text] [Related]
17. Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
Dixit PP; Dixit PP; Thore SN
Eur J Med Chem; 2016 Jan; 107():38-47. PubMed ID: 26562541
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
Pieroni M; Lilienkampf A; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Oct; 52(20):6287-96. PubMed ID: 19757815
[TBL] [Abstract][Full Text] [Related]
20. Novel 1-(4-substituted benzylidene)-4-(1-(substituted methyl)-2,3-dioxoindolin-5-yl)semicarbazide derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) and MDR-TB strain.
Raja S; Prakash CR
Arch Pharm Res; 2013 Apr; 36(4):411-22. PubMed ID: 23440582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
